Miocardite, COVID-19 e vaccini anti-sarscov2 negli adolescenti stiamo davvero riportando la verità sulle reazioni avverse ai farmaci del mondo reale?
Barra laterale dell'articolo
Contenuto principale dell'articolo
Abstract
in questo editoriale ci concentreremo sull'epidemiologia della miocardite/pericardite correlata a pazienti affetti da malattia COVID-19 o sottoposti a vaccinazione Anti-SarsCov2. Valuteremo i dati VAERS e EudraVigilance sulla miocardite/pericardite e individueremo le differenze tra farmacovigilanza passiva e attiva; inoltre valuteremo accuratamente il reale rapporto rischio/beneficio relativo alla somministrazione agli adolescenti dei farmaci vaccinali COVID-19.
Downloads
Dettagli dell'articolo
Questo lavoro è fornito con la licenza Creative Commons Attribuzione - Non commerciale - Non opere derivate 4.0 Internazionale.
Riferimenti bibliografici
- Michael K; Jason A; StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan. https://www.ncbi.nlm.nih.gov/books/NBK459259/
- Friman G, Wesslén L, Fohlman J, Karjalainen J, Rolf C. The epidemiology of infectious myocarditis, lymphocytic myocarditis and dilated cardiomyopathy. Eur Heart J. 1995 Dec;16 Suppl O:36-41. doi: 10.1093/eurheartj/16.suppl_o.36.
- Siripanthong B, Nazarian S, Muser D, Deo R, Santangeli P, Khanji M et al. Recognizing COVID-19–related myocarditis: The possible pathophysiology and proposed guideline for diagnosis and management. Heart Rhythm. 2020 Sep; 17(9): 1463–1471. doi: 10.1016/j.hrthm.2020.05.001
- Bozkurt B, Kamat I, Hotez P. Myocarditis With COVID-19 mRNA Vaccines. Circulation. 2021;144:471–484. DOI: 10.1161/CIRCULATIONAHA.121.056135
- Kerneis M, Bihan K. Salem J. COVID-19 vaccines and myocarditis, Arch Cardiovasc Dis, https://doi.org/10.1016/j.acvd.2021.06.001
- Deb A, Abdelmalek J, Iwuji K, Nugent K. Acute Myocardial Injury Following COVID-19 Vaccination: A Case Report and Review of Current Evidence from Vaccine Adverse Events Reporting System Database. Journal of Primary Care & Community Health, Volume 12: 1–5; https://doi.org/10.1177/21501327211029
- Muthukumar A, Narasimhan M, Li Q, Mahimainathan L, Hitto I, Fuda F. In-Depth Evaluation of a Case of Presumed Myocarditis After the Second Dose of COVID-19 mRNA Vaccine. Circulation. 2021;144:487–498. DOI: 10.1161/CIRCULATIONAHA.121.056038
- Morbidity and Mortality Weekly Report US Department of Health and Human Services/Centers for Disease Control and Prevention MMWR / July 9, 2021 / Vol. 70 / No. 27 977 Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices — United States, June 2021
- Muthukumar A, Narasimhan M, Li Q, Mahimainathan L, Hitto I, Fuda F. In-Depth Evaluation of a Case of Presumed Myocarditis After the Second Dose of COVID-19 mRNA Vaccine. Circulation. 2021;144:487–498. DOI: 10.1161/CIRCULATIONAHA.121.056038
- Morbidity and Mortality Weekly Report US Department of Health and Human Services/Centers for Disease Control and Prevention MMWR / July 9, 2021 / Vol. 70 / No. 27 977 Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices — United States, June 2021
- Jacqui W. Covid-19: Should we be worried about reports of myocarditis and pericarditis after mRNA vaccines? BMJ 2021;373:n1635 http://dx.doi.org/10.1136/bmj.n1635
- Muthukumar A, Narasimhan M, Li Q, Mahimainathan L, Hitto I, Fuda F. In-Depth Evaluation of a Case of Presumed Myocarditis After the Second Dose of COVID-19 mRNA Vaccine. Circulation. 2021;144:487–498. DOI: 10.1161/CIRCULATIONAHA.121.056038
- Morbidity and Mortality Weekly Report US Department of Health and Human Services/Centers for Disease Control and Prevention MMWR / July 9, 2021 / Vol. 70 / No. 27 977 Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices — United States, June 2021
- Jacqui W. Covid-19: Should we be worried about reports of myocarditis and pericarditis after mRNA vaccines? BMJ 2021;373:n1635 http://dx.doi.org/10.1136/bmj.n1635
- Levin A, Hanage W, Owusu Boaitey N, Cochran K, Walsh S, Meyerowitz Katz G.Assessing the age specifcity of infection fatality rates for COVID 19:systematic review, meta analysis, and public policy implications. European Journal of Epidemiology (2020) 35:1123–1138; https://doi.org/10.1007/s10654-020-00698-1
- R. Mei, et al., Myocarditis and pericarditis after immunization: Gaining insights through the Vaccine Adverse Event Reporting System, Int J Cardiol (2018), https://doi.org/10.1016/j.ijcard.2018.09.054
- Hazell L, Shakir S, Under-Reporting of Adverse Drug Reactions: A Systematic Review. Drug Safety 2006; 29 (5): 385-396 0114-5916/06/0005-0385
- Miller E, McNeil M, Moro P et al., The reporting sensitivity of the Vaccine Adverse Event Reporting System (VAERS) for anaphylaxis and for Guillain-Barré syndrome, Vaccine, https://doi.org/10.1016/j.vaccine.2020.09.072
- Bansal A, Agrawal A, Sharma L, Jain S. A Comparative Study of Active and Passive Adverse Drug Reaction Reporting Systems in Terms of False Reporting Rate Scr Med 2020;51(4):223-7. DOI:10.5937/scriptamed51-29065
- Liu Z, Meng R, Yang Y, Li K, Yin Z, Ren J. Active Vaccine Safety Surveillance: Global Trends and Challenges in China. Health Data Science Volume 2021, Article ID 9851067; https://doi.org/10.34133/2021/9851067
- Hause AM, Gee J, Baggs J, et al. COVID-19 Vaccine Safety in Adolescents Aged 12–17 Years — United States, December 14, 2020–July 16, 2021. MMWR Morb Mortal Wkly Rep 021;70:1053-1058. DOI: http://dx.doi.org/10.15585/mmwr.mm7031e1external icon
- Cevik M, Tate M, Lloyd O, Maraolo A, Schafers A, Ho A. SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: a systematic review and meta-analysis. Lancet Microbe 2021; 2: e13–22 Published Online November 19, 2020 https://doi.org/10.1016/ S2666-5247(20)30172-5
- Gazit S, Shlezinger R, Perez G, Lotan R, Peretz A, Ben-Tov A et al. Comparing SARS-CoV-2 natural immunity to vaccine-induced immunity: reinfections versus breakthrough infections. doi: https://doi.org/10.1101/2021.08.24.21262415